Learning Zone
Managing High-Risk NMIBC
The treatment landscape for high-risk non-muscle-invasive bladder cancer (NMIBC) is rapidly evolving. From the latest trial data to real-world insights, this resource aims to equip you with the information you need to select the right treatment options for your patients.
Check in here to:
- Review key points from the guidelines and practical advice from experts on the assessment of suspected bladder cancer
- Find the latest data on current and emerging immunotherapies for high-risk NMIBC, including updates from ASCO GU, EAU, and ASCO
- Listen to our expert podcast series for guidance on presentation and diagnosis of NMIBC, plus selecting the best care pathway for individual patients
- Hear healthcare professionals and patient advocates discuss how to optimize support for people with NMIBC
Developed by EPG Health. This content has been developed independently of the sponsor, Pfizer, which has had no editorial input into the content. EPG Health received funding from the sponsor to help provide healthcare professional members with access to the highest quality medical and scientific information, education and associated relevant content. This content is intended for healthcare professionals only.
Updates in your area
of interest
of interest
Articles your peers
are looking at
are looking at
Bookmarks
saved
saved
Days to your
next event
next event